Image

U.S. HSV1 Treatment Market – Industry Trends and Forecast to 2030

Healthcare

Image

U.S. HSV1 Treatment Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Upcoming Report
  • Jan 2023
  • Country Level
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

U.S. HSV1 Treatment Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 537.32 USD Million
Diagram Market Size (Forecast Year) USD 1,378.65 USD Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

U.S. HSV1 Treatment Market, By Type (Cold Sores, Genital Herpes), Occurrence (Primary Herpes, Recurrent Herpes), Treatment (Drugs, Vaccines), Route of Administration (Oral, Topical, Parenteral), Population Type (Neonates, Paediatrics and Adults), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others) – Industry Trends and Forecast to 2030. 

U.S. HSV1 Treatment Market Analysis and Size

Every year, the CDC reports an estimated 572,000 cases of genital herpes infections caused by the herpes simplex virus in the United States. Furthermore, individuals with HSV II infection are three times more likely to contract HIV if exposed. This has a significant impact on the global spread of HIV, as women are more vulnerable to both HIV and HSV II. As a result, the high prevalence of the herpes simplex virus is expected to drive market growth.

Data Bridge Market Research analyses that the HSV1 treatment market which is USD 537.32 million in 2022, is expected to reach USD 1378.65 million by 2030, at a CAGR of 12.5% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

U.S. HSV1 Treatment Market Scope and Segmentation  

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Cold Sores, Genital Herpes), Occurrence (Primary Herpes, Recurrent Herpes), Treatment (Drugs, Vaccines), Route of Administration (Oral, Topical, Parenteral), Population Type (Neonates, Paediatrics and Adults), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others)

Market Players Covered

Abbott (U.S.), Abcam plc. (U.K.), BIOMÉRIEUX (France), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), DiaSorin S.p.A. (Italy), Quidel Corporation (U.S.), Luminex Corporation (U.S.), Merck KGaA (Germany), QIAGEN (Germany), Norgen Biotek Corp. (Canada), Hologic Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), Teco Diagnostics (U.S.), GSK plc. (U.K.), Agenus Inc. (U.S.), Maruho Co., Ltd. (Japan), Sanofi (France)

Market Opportunities

  • Increasing prevalence of Herpes simplex virus-1

​​​​​​​

Market Definition

HSV is a contagious infection that spreads through saliva, sperm, and vaginal secretions and causes painful blisters or ulcers. Physical examinations, fluid sampling, and blood tests are commonly used to diagnose it. Antiviral medications, such as famciclovir, acyclovir, and valacyclovir, are currently the most effective treatment options for patients. These medications can be given orally or intravenously (IV) to help relieve symptoms, reduce the frequency and severity of outbreaks, and prevent virus transmission.

U.S. HSV1 Treatment Market Dynamics

Drivers

  • Rising health expenditures

Rising health expenditures, as well as government support to meet the growing demand for effective therapeutics, are encouraging companies to develop novel and innovative medicines. For instance, in June 2021, Innovative Molecules GmbH, a Munich-based drug development company, announced positive results in multiple HSV animal models of its novel drug candidate, IM-250, a second-generation helicase-primase inhibitor of HSV-1 and HSV-2. The company received $23.8 million in series A equity funding led by Life Sciences Partners and plans to begin Phase 1 clinical trials of IM-250 in late 2022 or early 2023.

Opportunities

  • Increasing prevalence of Herpes simplex virus-1

The increasing prevalence of Herpes simplex virus-1 encephalitis (HSE), a rare neurological disorder caused by the virus, is expected to drive segment growth. According to the National Organization for Rare Disorders (NORD), HSE affects both men and women equally and usually manifests itself in early childhood or adulthood. In the United States, the disorder accounts for 10% of all reported cases of encephalitis and nearly 2,000 reported cases of acute encephalitis.

Restraints/Challenges

  • High cost

HSL, HSV, and related spaces are adequate for selecting a single colour, they ignore much of the complexities of colour appearance. They essentially trade off perceptual relevance for computation speed, dating back to a time in computing history (high-end graphics workstations in the 1970s or mid-1990s consumer desktops) when more sophisticated models would have been too computationally expensive.

Furthermore, Patent expiry and continuous mutation in the virus lead to new strain to restrain market growth in the forecast period.  

This HSV1 treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the HSV1 treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In 2020, Bausch Health Companies Inc. launched a new telemedicine platform on www.dermatology.com in the United States. This website enables patients to consult with a healthcare professional in order to obtain a prescription on-demand for dermatology products such as Aldara and Solodyn. Aldara is an imiquimod cream used to treat HSV1. This website launch aided the company in attracting patients' attention and raising their awareness of major HSV1 treatment products.
  • In 2019, Dr. Reddy's Laboratories Ltd. relaunched Zenatane (Isotretinoin Capsules, USP) for HSV1 treatment. This product launch aided the company in expanding its HSV1 treatment product portfolio.

U.S. HSV1 Treatment Market Scope

The HSV1 treatment market is segmented on the basis of type, occurrence, treatment, route of administration, population type, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Cold Sores
  • Genital Herpes

 Occurrence

  • Primary Herpes
  • Recurrent Herpes

Treatment

  • Drugs
  • Vaccines

 Route of Administration

  • Oral
  • Topical
  • Parenteral

 Population Type

  • Neonates
  • Paediatrics
  • Adults

 Gender

  • Male
  • Female

End User

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

 Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The HSV1 treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for HSV1 treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the HSV1 treatment market. The data is available for historic period 2011-2021.

Competitive Landscape and HSV1 Treatment Market Share Analysis

The HSV1 treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to HSV1 treatment market.

Some of the major players operating in the HSV1 treatment market are:

  • Abbott (U.S.)
  • Abcam plc. (U.K.)
  • BIOMÉRIEUX (France)
  • Thermo Fisher Scientific, Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • DiaSorin S.p.A. (Italy)
  • Quidel Corporation (U.S.)
  • Luminex Corporation (U.S.)
  • Merck KGaA (Germany)
  • QIAGEN (Germany)
  • Norgen Biotek Corp. (Canada)
  • Hologic Inc. (U.S.)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Meridian Bioscience, Inc. (U.S.)
  • Teco Diagnostics (U.S.)
  • GSK plc. (U.K.)
  • Agenus Inc. (U.S.)
  • Maruho Co., Ltd. (Japan)
  • Sanofi (France)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The U.S. HSV1 Treatment Market size will be worth USD 1378.65 million by 2030 during the forecast period.
The U.S. HSV1 Treatment Market growth rate is 12.5% during the forecast period.
The Rising health expenditures is the growth driver of the U.S. HSV1 Treatment Market.
The type, occurrence, treatment, route of administration, population type, gender, end user, and distribution channel are the factors on which the U.S. HSV1 Treatment Market research is based.
The major companies in the U.S. HSV1 Treatment Market are Abbott (U.S.), Abcam plc. (U.K.), BIOMÉRIEUX (France), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), DiaSorin S.p.A. (Italy), Quidel Corporation (U.S.), Luminex Corporation (U.S.), Merck KGaA (Germany), QIAGEN (Germany), Norgen Biotek Corp. (Canada), Hologic Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), Teco Diagnostics (U.S.), GSK plc. (U.K.), Agenus Inc. (U.S.), Maruho Co., Ltd. (Japan), Sanofi (France).
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials